|
|
Article: Cervarix for protection against cervical cancer.(Pulse: The heartbeat of the marketplace)
- Article from:
- CME: Your SA Journal of CPD
- Article date:
- July 1, 2007
CopyrightCOPYRIGHT 2007 South African Medical Association. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
GlaxoSmithKline's (GSK's) cervical cancer candidate vaccine, Cervarix, demonstrated 100% efficacy in preventing precancerous lesions due to cancer-causing human papillomavirus types 16 and 18 for up to 5.5 years. This efficacy was demonstrated in an extended follow-up trial conducted by GSK, and is the longest duration of protection seen in any cervical cancer vaccine trial reported to date.
The candidate vaccine showed 68% vaccine efficacy against precancerous lesions (CIN2+) and 38% vaccine efficacy against abnormal Pap smears, regardless of the type of cancer-causing virus detected. These results suggest evidence of protection beyond what might be expected ...